INmune Bio (NASDAQ:INMB) Posts Earnings Results
INmune Bio (NASDAQ:INMB) reported quarterly earnings of ($0.40) per share, exceeding analysts' expectations of ($0.54) by $0.14. The stock traded down to $7.14, with a market cap of $189.86 million. Analysts have given the stock a consensus rating of "Buy" with a target price of $22.80. Recent upgrades include Maxim Group raising their target from $22.00 to $30.00 and Scotiabank increasing theirs from $22.00 to $23.00. INmune Bio focuses on developing drugs to treat various diseases by reprogramming the immune system.
INmune Bio (NASDAQ:INMB - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.14, Zacks reports.
INmune Bio Price Performance
Shares of INMB traded down $0.27 during mid-day trading on Friday, reaching $7.14. 61,057 shares of the company's stock were exchanged, compared to its average volume of 241,182. The stock has a market capitalization of $189.86 million, a PE ratio of -3.25 and a beta of 1.93. The business's fifty day simple moving average is $8.39 and its 200-day simple moving average is $6.37. INmune Bio has a 52-week low of $4.32 and a 52-week high of $12.72.
Analyst Upgrades and Downgrades
Several research firms have weighed in on INMB. Maxim Group lifted their target price on INmune Bio from $22.00 to $30.00 and gave the company a "buy" rating in a research report on Thursday, February 13th. Scotiabank increased their target price on INmune Bio from $22.00 to $23.00 and gave the company a "sector outperform" rating in a report on Tuesday, February 11th. RODMAN&RENSHAW raised INmune Bio to a "strong-buy" rating in a research report on Tuesday, January 28th. Finally, Rodman & Renshaw started coverage on INmune Bio in a research note on Tuesday, January 28th. They set a "buy" rating and a $23.00 target price for the company. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $22.80.
View Our Latest Analysis on INMB
About INmune Bio
(Get Free Report)INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
See Also
- Five stocks we like better than INmune Bio
- Stock Sentiment Analysis: How it Works
- Buy the Chewy Stock Reversal? Here’s Why Now Is the Time
- How Technical Indicators Can Help You Find Oversold Stocks
- Ibotta Stock: Why the Buyback Looks Like a Bullish Bet
- What is the S&P 500 and How It is Distinct from Other Indexes
- Joby Aviation Stock: Analyst Confidence and Smart Money Align
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in INmune Bio Right Now?
Before you consider INmune Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and INmune Bio wasn't on the list.
While INmune Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
